24/7 Market News Snapshot 21 April, 2025 – Clearmind Medicine Inc. Common Shares (NASDAQ:CMND)
DENVER, Colo., 21 April, 2025 (www.247marketnews.com) – (NASDAQ:CMND) are discussed in this article.
Clearmind Medicine Inc. (CMND) is currently navigating a challenging period in the financial market, with shares trading at $1.030 in pre-market, reflecting a notable decline of approximately 8.03% from the previous closing price of $1.120. This downturn is characterized by increased selling pressure, as evidenced by a volume of 118.30K shares traded. Such a steep drop suggests a potential shift in market sentiment towards the company, possibly driven by broader economic factors or specific company-related news. Investors are advised to monitor critical support levels around $1.00, as a sustained fall beneath this threshold could exacerbate bearish momentum, prompting caution among potential investors.
In a proactive move, Clearmind Medicine is slated to host an engaging live webinar titled “Gazing Through the Crystal Ball” on May 21, 2025, at 12:00 PM ET. This event will gather a panel of esteemed experts who will delve into the evolving realms of psychedelic science and business, highlighting significant recent changes in FDA regulations and the political climate surrounding this field.
The webinar features notable figures such as Dr. Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS), renowned for his contribution to safe and ethical psychedelic utilization. Dr. Robin Carhart-Harris, a prominent psychedelic neuroscientist from the University of California, San Francisco, will share insights from his clinical research on substances like psilocybin. Additionally, Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, will discuss the company’s innovative approach to treating Alcohol Use Disorder (AUD) with its product CMND-100. Completing the panel, Mark Haden, Clearmind’s VP of Business Development, will provide insights into drug policy reform.
Participants interested in this unique opportunity to gain perspectives from industry leaders and discuss the future of psychedelic medicine are encouraged to register for the event via Clearmind Medicine’s official website. The webinar aims to facilitate rich dialogue around groundbreaking developments within the psychedelic therapeutics sector.
Related news for (CMND)
- Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
- Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
- 24/7 Market News Snapshot 19 September, 2025 – Clearmind Medicine Inc. Common Shares (NASDAQ:CMND)
- ARK Sets Sail, Crypto Crossovers and Digital Asset Arms Race
- Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center